Fig. 2From: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or olderSVR12 rates for each parameter. a age, b gender, c genotype, d HCV viral load, e liver status, f FIB-4 index, g prior HCV treatment, h history of HCC, i presence of NS5A RASs, j eGFRBack to article page